基于代谢组学的肿瘤恶液质差异性代谢物研究进展  

Advances in metabolomics-based studies of differential metabolites in cancer cachexia

作　　者：徐静 陈美宇 张大猛 杜沛龙 朱馨婷 韩冷 郭澄[1] 杨全军[1,2] Xu Jing;Chen Meiyu;Zhang Dameng;Du Peilong;Zhu Xinting;Han Leng;Guo Cheng;Yang Quarjun(Department of Pharmacy,Shanghai Sixth People's Hospital Affiliated Shanghai Jiaotong University School of Medicine,Shanghai 200233,China;Shanghai University of Medicine&Health Science,Shanghai 201318,China)

机构地区：[1]上海交通大学医学院附属第六人民医院,上海200233 [2]上海健康医学院,上海201318

出　　处：《肿瘤代谢与营养电子杂志》2024年第3期421-428,共8页Electronic Journal of Metabolism and Nutrition of Cancer

基　　金：国家自然科学基金(82272925);上海市浦江人才(21PJ1411900);上海市第六人民医院院级管理类科研基金(X-4221);上海市第六人民医院医疗服务能级提升工程医政管理优化项目(X-4108)。

摘　　要：肿瘤恶液质是一种复杂的多因素系统综合征,以代谢紊乱介导肌肉萎缩和体重减轻为主要特征,干扰治疗方案实施,导致患者生活质量下降和生存期缩短。肿瘤恶液质影响50%~80%的肿瘤患者,胰腺癌、肺癌、胃癌等肿瘤更有高达85%以上的恶液质发生率,且20%的肿瘤患者因为恶液质代谢的巨大消耗而直接死亡。肿瘤恶液质发病机制非常复杂,目前关于肿瘤恶液质的代谢发病特征、发病机制和药物防治研究备受关注。代谢组学技术通过研究机体代谢物构成和浓度的变化揭示疾病代谢发病特征,近年来广泛用于肿瘤和代谢性疾病的特征和生物标志物研究,阐明多组织脏器代谢相互作用关系。本文总结肿瘤恶液质的代谢改变特征及其代谢途径,阐明肿瘤恶液质的基本改变机制和生物标志物研究现状,尤其是不同类型肿瘤介导恶液质发病的机制及其临床代谢差异,比较临床样本和模型动物肿瘤恶液质代谢轮廓和生物标志物,分析不同肿瘤恶液质的代谢相互作用关系,以期为肿瘤恶液质的诊断和防治研究提供新思路,为药物靶点和临床干预开发提供新思路。Cancer cachexia is a cooplex multifactorial systemic syndrome that characterized by metabolic disorders mediating muscle atrophy and weight loss.Cancer cachexia is not only a ontraindication to the comprehensive cancer treatment such as chemotherapy,but also a deteriorating stale with decreasing quality of life and short survival.Cancer cachexia occurs in 50%-80%of cancer patients,with an incidence of over 85%in patients with pancreatie,lung and gastrie cancer.In addition,20%of cancer patients die as a result of the enorous wasting asciaed with cachexia.Metabolomics technology reveals the metabolic pathogenesis of diseases through the study of changes in the coposition and concentration of metabolites,and has been widely used in recent years for the characterisation and biomarker studies of tumours and metabolic diseases to elucidate the metabolie interactions of multiple tissues.In the present study,we summarised the metabolie changes and pathways of cancer cachexia to elucidate the fundamental metabolie reprogramming of cancer cachexia.We reviewed the current status of biomarker research and the mechanism of cancer cachexia rsuling from diferent types of cancer.By coparing the metabolic profiles of cancer cachexia from elinical samples and animal models,we analysed the metablie interactions of dfferent cancer cachexias.The present study not only provides new ideas for the diagnosis and prevention of eancer cachexia,but also new strategies for dnug target research and elinical intervention research.

关 键 词：肿瘤恶液质 体重减轻 代谢组学 骨骼肌萎缩 生物标志物 

分 类 号：R730.2[医药卫生—肿瘤]